CTLA4 and mesothelioma: CTLA-4 (CD152) was the first immunoregulatory molecule to be targeted for therapeutic purposes utilizing the humanized antibody Ipilimumab approved by FDA and EMA in 2011, initially for melanoma (18), soon followed by Tremelimumab for mesothelioma (19, 20).